Artificial Intelligence System for Multi-Cancer Detection Support

Descripción del proyecto

Una herramienta de diagnóstico de alta precisión para detectar los primeros estadios de tumores malignos

La supervivencia de los pacientes oncológicos está relacionada sobre todo con la etapa de evolución de la enfermedad en el momento del diagnóstico. Una empresa incipiente rumana, Artificial Intelligence Expert (AIE), desarrolla tecnologías para facilitar el diagnóstico y cribaje tempranos de varios tipos de tumores malignos. AIE se centra en la transición a biopsias líquidas, micromatrices y secuenciación de nueva generación (SNG) para el diagnóstico molecular. La tecnología detecta tumores malignos en los primeros estadios utilizando microARN circulantes en lugar del ADN tumoral circulante o las células cancerosas circulantes empleados actualmente. La detección más temprana de la evolución tumoral es muy precisa y emplea inteligencia artificial para analizar los perfiles de microARN a partir de datos de matrices y de SNG. El proyecto AI-MICADIS, financiado con fondos europeos, permite a la empresa identificar asociaciones y optimizar la mejor estrategia de negocio para comercializar la tecnología.

Objetivo

Need – Each year, over 8M people die of cancer and now the World Health Organization is urging governments to accelerate action to reduce premature mortality. The stage of a cancer progression at the time of diagnosis is strongly associated with patient survival. Unfortunately, the current diagnostic tests and screening tools have very disappointing accuracy rates and many patients remain undiagnosed.

Solution – Artificial Intelligence Expert (AIE) is a Romanian start-up company with a ground-breaking solution that will enable early diagnoses and screening for a wide variety of cancers. AIE aims to leverage the fast transition to liquid biopsies, microarray and next generation sequencing (NGS) for molecular diagnostics. AIE can detect cancer at the earliest stages by using circulating microRNAs instead of the commonly used circulating tumour DNA or circulating cancer cells. AIE is developing an extremely accurate diagnostic tool for detection of the earliest stages of cancer progression using powerful Deep Learning Artificial Intelligence to analyse microRNA profiles from microarray and next generation sequencing (NGS) data.

Market opportunity – The fast increase of big data collection and the associated need to extract knowledge from it drives the AI in healthcare market, which is growing at a CAGR of 53% to $8B by 2022. This market growth is fuelled by a strong growth of the NGS diagnostic market, which is growing at a CAGR of 73%.

Competition – The competition is focusing on optimizing currently used circulating tumour DNA detection tools and simpler machine learning models, that extract a small number of meaningful biomarkers. This keeps the competitor’s data processing needs low, but infringes on the tests’ accuracy and sensitivity.

Feasibility assessment – AIE will use the SMEi phase 1 funding to identify partnerships, perform user involvement study, set out a regulatory path, and optimize the best business strategy to bring the AI-MICADIS to the market.

Ámbito científico

Programa(s)

Tema(s)

EIC-SMEInst-2018-2020 - SME instrument

Convocatoria de propuestas

H2020-EIC-SMEInst-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEInst-2018-2020-1

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

ARTIFICIAL INTELLIGENCE EXPERT SRL

Aportación neta de la UEn

€ 50 000,00

Dirección

Strada alexandru vlahuta, bloc lama c, ap.45
400310 Cluj napoca
Rumanía

Región

Macroregiunea Unu Nord-Vest Cluj

Tipo de actividad

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Enlaces

Contactar con la organización

Participación en los programas de I+D de la UE

Red de colaboración de HORIZON

Otras fuentes de financiación

€ 21 429,00